Symyx Shares Fall after Ending Talks with Possible Buyer

Shares of Symyx Technologies fell 14% Wednesday, a day after the company said it ended talks with Certara, which revoked its offer to buy the scientific research provider for $6.75 a share.

Earlier this month, Symyx agreed to provide information about itself and help Certara, the parent of certain scientific software makers, and its private equity sponsor Vector Capital, with the due diligence process.

Before it received Certara's offer, the company had agreed to merge with Accelrys Inc in a stock deal, which valued Symyx at a little more than $5 a share, or about $175 million. After the merger, each company would own about 50% of the combined entity.

In a regulatory filing on Tuesday, Symyx posted Certara's letter, which said it could offer a substantial cash premium over Accelrys' offer, but not $6.75 a share.

Symyx said it does not have a superior offer under consideration.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.